Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...

In a recent industry report focused on Biotechnology stocks, particularly those innovating in neurology and psychiatry, ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...

Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to prescribe Nurtec.

A Super Bowl ad for weight loss medications from telehealth company Hims & Hers is optimized to engage and infuriate ...